Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
On August 2, 2021, Immunovant announced a strategic investment of $200 million from Roivant Sciences. This investment will support the development of IMVT-1401 across multiple indications, enhancing Immunovant's financial position with a post-investment cash balance of approximately $600 million. Roivant acquired 17,021,276 shares at $11.75 each, increasing its ownership from 57.5% to 63.8%. Immunovant plans to initiate pivotal trials for myasthenia gravis and resume trials in WAIHA and TED over the next 12 months.
Immunovant (Nasdaq: IMVT) announced plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA). The company reported a cash balance of approximately $400 million as of March 31, 2021, and net losses increased to $107.4 million for the fiscal year, up from $66.4 million in 2020. A data review indicated that IMVT-1401 has a broader therapeutic window than expected, with manageable lipid elevations. The company intends to initiate multiple clinical studies over the next year as part of its developmental strategy.
Immunovant (Nasdaq: IMVT) reported its financial results for the third quarter and nine months ended December 31, 2020. The company ended the quarter with approximately $422 million in cash. However, it voluntarily paused dosing in its clinical trials for IMVT-1401 due to elevated cholesterol levels in patients. R&D expenses rose to $21.1 million, up from $5.0 million a year earlier, while net loss for the quarter was $31.8 million ($0.32 per share), compared to $11.3 million last year. Ongoing reviews and future updates are expected in Q2 2021.
Immunovant (Nasdaq: IMVT) has appointed Dr. Rita Jain as Chief Medical Officer, bringing over 20 years of drug development expertise. Dr. Jain's extensive experience in clinical trials, particularly in immunology and inflammation, positions her to lead multiple Phase 3 programs for IMVT-1401. Additionally, due to COVID-19-related site closures, results for key trials of IMVT-1401 are now delayed, with expectations for updates in Q2 and Q3 of 2021. The company remains optimistic about IMVT-1401's potential in various therapeutic areas.
Immunovant reported its fiscal second quarter results ending September 30, 2020, with approximately $444 million in cash and a net loss of $20.8 million ($0.25 per share). R&D expenses rose to $12.0 million primarily due to increased clinical trial costs. The company appointed Michael Elliott as Chief Scientific Officer and reported positive results from its IMVT-1401 trial for Myasthenia Gravis. Additionally, they raised $188 million through a public equity offering. Upcoming results for ongoing trials are anticipated in 2021.
Immunovant, Inc. (Nasdaq: IMVT) has successfully closed its underwritten public offering of 6,060,606 shares of common stock at $33.00 per share, raising approximately $200.0 million in gross proceeds. This includes the full exercise of an underwriters’ option for an additional 790,513 shares. The offering was managed by SVB Leerink, Guggenheim Securities, and Chardan, with LifeSci Capital and Baird as co-lead managers. The registration statements for these securities became effective on September 1, 2020.
Immunovant, Inc. (Nasdaq: IMVT) appointed Michael Elliott, MBBS, PhD as Chief Scientific Officer. He brings over 23 years of R&D experience, including 17 years at Johnson & Johnson, where he led the development of innovative immunology products. Elliott will oversee the advancement of IMVT-1401, a novel antibody treatment for autoimmune diseases. The company is currently in a productive phase with three programs in Phase 2. CEO Pete Salzmann highlighted Elliott's expertise in identifying best-in-class opportunities, vital for the company’s growth.
Immunovant, Inc. (Nasdaq: IMVT) reported its financial results for the fiscal first quarter ending June 30, 2020, revealing a net loss of $26.7 million, up from $20.1 million a year prior. Cash reserves stood at approximately $280.3 million. Research and development (R&D) expenses decreased by $1.6 million to $16.9 million; however, adjusting for a one-time milestone payment in the prior year, R&D expenses actually increased by $8.5 million due to higher clinical trial costs. General and administrative (G&A) expenses surged by $8.1 million to $9.7 million, attributed to rising personnel costs and legal fees.
Immunovant, Inc. (Nasdaq: IMVT) announced that warrant holders have until June 15, 2020, to exercise 11.5 million outstanding warrants, potentially raising $66.125 million at a price of $11.50 per share. The warrants are subject to mandatory redemption if its stock price stays above $16.50 for 20 trading days. Additionally, Immunovant is triggering the issuance of 10 million shares to former shareholders after meeting specific price conditions. The company remains focused on developing treatments for autoimmune diseases.